haddenham venex class 2 (23-32mmhg) armsleeve lymphoedema garment regular medium
23-32mmhg) armsleeve lymphoedema garment regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve lymphoedema garment extra wide regular medium
23-32mmhg) armsleeve lymphoedema garment extra wide regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve with grip top and mitten lymphoedema garment regular medium
23-32mmhg) armsleeve with grip top and mitten lymphoedema garment regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve with grip top and mitten lymphoedema garment extra wide regular medium
23-32mmhg) armsleeve with grip top and mitten lymphoedema garment extra wide regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve with grip top lymphoedema garment regular medium
23-32mmhg) armsleeve with grip top lymphoedema garment regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve with grip top lymphoedema garment extra wide regular medium
23-32mmhg) armsleeve with grip top lymphoedema garment extra wide regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve with mitten lymphoedema garment regular medium
23-32mmhg) armsleeve with mitten lymphoedema garment regular medium mocha (haddenham healthcare ltd -
haddenham venex class 2 (23-32mmhg) armsleeve with mitten lymphoedema garment extra wide regular medium
23-32mmhg) armsleeve with mitten lymphoedema garment extra wide regular medium mocha (haddenham healthcare ltd -
betaloc cr 23.75
astrazeneca limited - metoprolol succinate 23.75mg; - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension
23-valent pneumococcal polysaccharide vaccine injection
23-valent pneumococcal polysaccharide vaccine - injection - 0.5ml/dose/syringe which consists of 23 serotypes - vaccines